Vor Biopharma (VOR)
(Delayed Data from NSDQ)
$2.18 USD
+0.07 (3.32%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.16 -0.02 (-0.92%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VOR 2.18 +0.07(3.32%)
Will VOR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VOR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VOR
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross
VOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VOR
Vor Bio (VOR) Appoints Dallan Murray as Chief Commercial Officer
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer | VOR ...
Vor Bio appoints Murray as Chief Commercial Officer
Vor Bio (VOR) Strengthens Board with New Appointments | VOR Stock News
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. ...